Utility of Perfusion MRI to Detect Radiation Necrosis in Patients With Brain Metastases
| Status: | Recruiting |
|---|---|
| Conditions: | Brain Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 2/2/2019 |
| Start Date: | November 28, 2018 |
| End Date: | January 31, 2020 |
| Contact: | Hui-Kuo Shu, MD, PhD |
| Email: | hgshu@emory.edu |
| Phone: | 404-778-3473 |
Diagnostic Accuracy of Dynamic Susceptibility Contrast (DSC) Perfusion MRI to Determine Radiation Necrosis Versus Tumor Progression in Brain Metastases Treated With Stereotactic Radiosurgery
This trial studies how well dynamic susceptibility contrast-magnetic resonance imaging (MRI)
works in determining radiation necrosis and tumor progression in participants with cancer
that has spread to the brain and are being treated with radiation therapy. Diagnostic
procedures, such as dynamic susceptibility contrast-MRI, may improve the ability to determine
indeterminate post-treatment changes seen on imaging after radiation therapy.
works in determining radiation necrosis and tumor progression in participants with cancer
that has spread to the brain and are being treated with radiation therapy. Diagnostic
procedures, such as dynamic susceptibility contrast-MRI, may improve the ability to determine
indeterminate post-treatment changes seen on imaging after radiation therapy.
PRIMARY OBJECTIVE:
I. To prospectively determine the sensitivity and specificity of dynamic susceptibility
contrast (DSC)-MRI parameters in detecting tumor recurrence versus radiation necrosis for
brain metastases treated with stereotactic radiosurgery (SRS).
SECONDARY OBJECTIVES:
I. To correlate radiographic diagnoses with pathologic diagnoses when surgical resection is
clinically indicated.
II. To correlate baseline relative cerebral blood volume (rCBV) values and other hemodynamic
parameters with tumor primary histology.
III. To assess overall survival, local failure, distant brain failure and neurologic death.
OUTLINE:
Participants undergo a diagnostic MRI with and without contrast and treatment planning DSC
perfusion MRI series before receiving SRS at 4-6 weeks after SRS, and then every 3 months
unless clinically indicated sooner.
I. To prospectively determine the sensitivity and specificity of dynamic susceptibility
contrast (DSC)-MRI parameters in detecting tumor recurrence versus radiation necrosis for
brain metastases treated with stereotactic radiosurgery (SRS).
SECONDARY OBJECTIVES:
I. To correlate radiographic diagnoses with pathologic diagnoses when surgical resection is
clinically indicated.
II. To correlate baseline relative cerebral blood volume (rCBV) values and other hemodynamic
parameters with tumor primary histology.
III. To assess overall survival, local failure, distant brain failure and neurologic death.
OUTLINE:
Participants undergo a diagnostic MRI with and without contrast and treatment planning DSC
perfusion MRI series before receiving SRS at 4-6 weeks after SRS, and then every 3 months
unless clinically indicated sooner.
Inclusion Criteria:
- Histologically proven diagnosis of invasive malignancy with at least radiographic
evidence of intracranial disease as seen on MRI.
- At least one identifiable intracranial lesion ≥ 1 cm in diameter enrolled within 4
weeks of diagnosis.
- Eastern Cooperative Oncology Group (ECOG) performance status ≥ 2.
Exclusion Criteria:
- Planned whole-brain radiotherapy (WBRT) with boost.
- Leptomeningeal disease.
- Inadequate renal function (estimated glomerular filtration rate [eGFR] > 30
ml/min/1.73 m²) or contrast allergy.
- Non-MRI compatible pacemaker with pacemaker dependence.
We found this trial at
2
sites
Click here to add this to my saved trials
Click here to add this to my saved trials